[{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"Apricoxib","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targovax \/ IOVaxis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ IOVaxis Therapeutics"},{"orgOrder":0,"company":"Targovax","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Apricoxib","moa":"||KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Targovax \/ Agenus","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ Agenus"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The financing enables ARTBIO's ongoing clinical development of its lead program AB001 (212Pb-NG001) for the treatment of prostate cancer and will advance its AlphaDirect™ Pb212 isolation technology.

                          Product Name : AB001

                          Product Type : Radiolabelled Compounds

                          Upfront Cash : Undisclosed

                          June 21, 2023

                          Lead Product(s) : 212-Pb NG001

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : F-Prime Capital

                          Deal Size : $23.0 million

                          Deal Type : Financing

                          blank

                          02

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore...

                          Product Name : TG01

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 01, 2021

                          Lead Product(s) : Apricoxib

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : IOVaxis Therapeutics

                          Deal Size : $3.0 million

                          Deal Type : Licensing Agreement

                          blank